Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial

Optimal two-stage designs for phase II clinical trials

Richard Simon · Controlled Clinical Trials · 1989 · 3.6K citations

Public Health, Biostatistics, Experimental Design +10

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

Ian Judson, Jaap Verweij, Hans Gelderblom et al. · The Lancet Oncology · 2014 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +13

Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study

Nicolas Penel, Binh Bui, Jacques‐Olivier Bay et al. · Journal of Clinical Oncology · 2008 · 693 citations · Full text

Medicine, Oncology, Pharmacology +10

Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial

Martee L. Hensley, Robert G. Maki, Ennapadam Venkatraman et al. · Journal of Clinical Oncology · 2002 · 688 citations

Medicine, Oncology, Pharmacokinetics +14

Incidence of Sarcoma Histotypes and Molecular Subtypes in a Prospective Epidemiological Study with Central Pathology Review and Molecular Testing

Françoise Ducimetière, A. Lurkin, Dominique Ranchère‐Vince et al. · PLoS ONE · 2011 · 546 citations · Full text

Medicine, Oncology, Pathology +17